The FDA approved yttrium-90 resin microspheres (SIR-Spheres Y-90; Sirtex Medical), also known as radioembolization or selective internal radiation therapy, for inoperable hepatocellular carcinoma. The ...

In 1775, English surgeon Percivall Pott discovered that exposure to soot in chimneys caused scrotal cancer in chimney sweeps, the first time an agent found in the workplace was directly connected to ...

AbstractTo explore how early cancers can be detected prior to clinical signs or symptoms, we assessed prospectively collected serial plasma samples from the Atherosclerosis Risk in Communities study, ...

Abstract. Ki-rasmutations are thought to be early events in the carcinogenic process leading to colon tumors. Dietary factors associated with colon cancer may be associated with these mutations. Data ...

Abstract. PTEN is a tumor suppressor frequently inactivated in brain, prostate, and uterine cancer. It acts as a phosphoinositide phosphatase and consists of an amino-terminal phosphatase domain ...

Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...

Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

Homologous recombination is a high-fidelity DNA repair mechanism essential for maintaining genome stability. Impairment of this pathway, often due to BRCA1 or BRCA2 inactivation, leads to homologous ...

A new AI platform turns a general-purpose language model into an autonomous clinical agent that can analyze diagnostic data, interpret imaging and pathology, and generate treatment plans for patients ...

CAR T-cell therapy can successfully treat chemotherapy-resistant B-cell malignancies but has limited effectiveness against solid tumors. The authors report that a fully human CAR targeting the STn ...

The FDA today granted accelerated approval to linvoseltamab (Lynozyfic, Regeneron) for adults with relapsed or refractory multiple myeloma who have already received at least four therapeutic regimens.